AstraZeneca (LON:AZN) Earns Hold Rating from Deutsche Bank Aktiengesellschaft

Key Points

• Deutsche Bank has reiterated a "hold" rating on AstraZeneca (AZN) with a price objective of £110 ($146.90), indicating a potential downside of 2.14% from the stock's previous close.
• Other analysts, including Shore Capital and Berenberg Bank, have issued "buy" ratings with higher price targets of £135 ($180.29) and GBX 140 ($1.87), respectively.
• AstraZeneca's shares opened at £112.40 ($150.11) and have seen a 52-week range from £9,573.51 ($127.85) to £133.88 ($178.79).

Deutsche Bank Aktiengesellschaft reaffirmed their hold rating on shares of AstraZeneca (LON:AZN - Free Report) in a research report report published on Wednesday morning, MarketBeat Ratings reports. The firm currently has a £110 ($146.06) price objective on the biopharmaceutical company's stock.

AZN has been the subject of several other reports. Shore Capital reissued a "buy" rating and issued a £135 ($179.26) price target on shares of AstraZeneca in a research report on Tuesday, July 29th. Berenberg Bank reissued a "buy" rating and issued a GBX 140 ($1.86) price target on shares of AstraZeneca in a research report on Friday, May 16th.

AstraZeneca Stock Down 1.9%

Shares of AZN stock traded down GBX 220 ($2.92) during mid-day trading on Wednesday, hitting £111.04 ($147.44). The stock had a trading volume of 1,861,434 shares, compared to its average volume of 11,168,884. AstraZeneca has a 12-month low of GBX 9,573.51 ($127.12) and a 12-month high of £133.88 ($177.77). The firm has a market capitalization of £213.64 billion, a P/E ratio of 30.44, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The firm's 50-day moving average is £105.77 and its two-hundred day moving average is £108.82. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.